MindMaze Therapeutics Holding SA (SIX: MMTX), a global leader in scalable precision neurotherapeutics, announced the results of its Annual General Meeting held earlier today. Shareholders approved all proposals submitted by the Board of Directors, except the proposed increase in conditional share capital, which did not obtain the required qualified majority.
Shareholders re-elected Walid Hanna, Olaf Blanke and Martin Reiss to the Board of Directors and elected Brad Hollinger, Founder, Chairman and Chief Executive Officer of Vibra Healthcare, and Zach Henderson, Chief Executive Officer of MindMaze Therapeutics, as new members of the Board of Directors. The addition of Hollinger and Henderson brings fresh perspectives to the board as the company continues to expand its footprint in neurotherapeutics.
In addition, shareholders approved the 2025 Annual Report and financial statements, the appropriation of available earnings, the discharge of the members of the Board of Directors and the Executive Committee, the re-election of Walid Hanna as Chairman of the Board of Directors, the elections to the Nomination and Compensation Committee, the re-election of the Independent Proxy and the statutory auditor, the compensation proposals for the Board of Directors and Executive Committee, and the consultative vote on the 2025 Compensation Report.
The rejection of the conditional share capital increase is notable, as it may impact the company's ability to issue new shares for future financing or acquisitions without seeking further shareholder approval. However, the approval of all other proposals indicates strong shareholder support for the current strategic direction and governance.
MindMaze Therapeutics is dedicated to redefining the recovery trajectory for patients with neurological disorders through scalable, precision neurotherapeutics. By integrating advanced software, proprietary sensors, and AI-driven data analytics, the company provides a seamless continuum of care from acute hospital care to outpatient treatment to home-based therapy. Its FDA-cleared and CE-marked products address the systemic shortage of specialized clinicians, offering scalable, reimbursable solutions for stroke, Parkinson’s disease, and other neurological disorders.
The company's robust R&D pipeline and extensive library of rigorous clinical validation position it to operationalize the future of neurorestorative medicine. For more information, visit www.mindmazetherapeutics.com.
Detailed voting results will be published on the company’s website later today, as stated in the press release. The AGM results underscore the company's commitment to transparency and shareholder engagement, while the new board members are expected to contribute valuable expertise as MindMaze Therapeutics advances its mission.
